Share on StockTwits

Cytosorbents Corp (NASDAQ:CTSO) CFO Kathleen P. Bloch bought 65,000 shares of the stock on the open market in a transaction dated Tuesday, September 2nd. The stock was purchased at an average cost of $0.23 per share, for a total transaction of $14,950.00. The transaction was disclosed in a filing with the SEC, which is available at this link.

Shares of Cytosorbents Corp (NASDAQ:CTSO) traded down 2.96% during mid-day trading on Wednesday, hitting $0.2231. The stock had a trading volume of 417,056 shares. Cytosorbents Corp has a 52-week low of $0.09 and a 52-week high of $0.35. The stock’s 50-day moving average is $0.25 and its 200-day moving average is $0.24. The company’s market cap is $69.3 million.

Cytosorbents Corp (NASDAQ:CTSO) last announced its earnings results on Tuesday, August 12th. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.01). On average, analysts predict that Cytosorbents Corp will post $-0.03 earnings per share for the current fiscal year.

Separately, analysts at HC Wainwright initiated coverage on shares of Cytosorbents Corp in a research note on Monday, August 18th. They set a “buy” rating and a $1.00 price target on the stock.

CytoSorbents Corporation is a development stage critical care focused company using blood purification to treat life-threatening illnesses.

Receive News & Ratings for Cytosorbents Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.